Ownership
Private
Employees
~100
Therapeutic Areas
Oncology
Stage
Preclinical
Modalities
Antibody-drug conjugate (ADC)

Tubulis General Information

Developing next-generation ADCs with improved stability and reduced toxicity. Recently signed $1B deal with Bristol Myers Squibb for ADC development.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Berlin,
Germany

Drug Pipeline

No pipeline data available

For full access to Tubulis's pipeline data

Book a demo

Key Partnerships

Bristol Myers Squibb

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Tubulis Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Tubulis's complete valuation and funding history, request access »

Tubulis Investors

EQT Life Sciences
Investor Type: Venture Capital
Holding: Minority
Nextech Invest Ltd
Investor Type: Venture Capital
Holding: Minority